CoChat
Sign Up
Cited by 9Allergic Rhinitis and SensitizationFood Allergy and Anaphylaxis ResearchAsthma and respiratory diseases

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Quality of life in allergic rhinitis patients treated with intralymphatic immunotherapy (ILIT): A 19-year follow-up

Open access
Adlany, Yasmin K., Šošić, Lara, Senti, Gabriela, Lang, Claudia C.V., Wüthrich, Brunello, Kündig, Thomas M., Johansen, Pål·2023·Journal of Allergy and Clinical Immunology: Global
DOI 10.1016/j.jacig.2022.09.007PMC PMC10509981
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: In 2002-2005, we conducted a phase I/II clinical trial where a new allergy immunotherapy (AIT) route was introduced: intralymphatic immunotherapy (ILIT). Ultrasound guidance allowed injection of allergen directly into inguinal lymph nodes. Grass pollen-allergic patients received 3 injections with 1-month intervals. The short ILIT was more patient-friendly, required lower dosing, and was comparable with SCIT regarding short-term efficacy, which was used as a reference. Objective: Nineteen years after ILIT, the same patients were followed up to assess the long-term effect on quality of life and efficacy of the treatment. Methods: Patients who received ILIT and SCIT in 2002-2005 and an additional group of patients, who completed SCIT in 2015-2018, were recruited. All participants received a trial-specific in-house questionnaire and a standardized Rhinoconjunctivitis Quality of Life Questionnaire. Data were recorded off- (February 2021) and on- (May-June 2021) season. Descriptive statistics were applied. Results: Of 58 and 54 patients who originally received ILIT or SCIT, 25 (43%) and 29 (54%) patients, respectively, returned the questionnaires for analysis. Four (16%) and 3 (11%) of the ILIT and SCIT patients, respectively, developed complete protection against grass pollen-mediated rhinitis, whereas another 15 (60%) and 20 (69%) expressed satisfaction with the received AIT. In both groups, any persistent symptoms were reported as mild. Medication usage in the ILIT and SCIT groups was comparable. Nineteen (76%) and 23 (79%) patients, respectively, expressed satisfaction with their AIT. Conclusions: Grass pollen ILIT leads to long-term significant improvement in rhinitis-associated quality of life 19 years after treatment, and the ILIT quality-of-life effect was not inferior to that of SCIT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacig.2022.09.007

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Allergen-specific immunotherapy (ASIT) represents an effective treatment for IgE-mediated allergies.

    “Allergen-specific immunotherapy (ASIT) represents an effective treatment for IgE-mediated allergies, including subcutaneous immunotherapy (SCIT), sublingual immunotherapy (SLIT), and intralymphatic immunotherapy (ILIT) (Figure 2f).”

    From Advance in Managing Indoor Cat Allergen Proteins: Molecular Insights, Detection, and Control (2025) · cites this paper as [160]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 40

  1. Wuthrich, 1995, Prevalence of atopy and pollinosis in the adult population of Switzerland (SAPALDIA study). Swiss Study on Air Pollution and Lung Diseases in Adults, Int Arch Allergy Immunol, 106, 149, 10.1159/000236836 · DOI · Paper page
  2. Wuthrich, 1996, IgE levels, atopy markers and hay fever in relation to age, sex and smoking status in a normal adult Swiss population. SAPALDIA (Swiss Study on Air Pollution and Lung Diseases in Adults) Team, Int Arch Allergy Immunol, 111, 396, 10.1159/000237398 · DOI
  3. Bauchau, 2004, Prevalence and rate of diagnosis of allergic rhinitis in Europe, Eur Respir J, 24, 758, 10.1183/09031936.04.00013904 · DOI · Paper page
  4. Passalacqua, 2006, Local nasal specific immunotherapy for allergic rhinitis, Allergy Asthma Clin Immunol, 2, 117, 10.1186/1710-1492-2-3-117 · DOI
  5. Calderon, 2011, European Academy of Allergy and Clinical Immunology Task Force report on ‘dose-response relationship in allergen-specific immunotherapy, Allergy, 66, 1345, 10.1111/j.1398-9995.2011.02669.x · DOI
  6. Liu, 2021, Compliance, efficacy, and safety of subcutaneous and sublingual immunotherapy in children with allergic rhinitis, Pediatr Allergy Immunol, 32, 86, 10.1111/pai.13332 · DOI
  7. Pfaar, 2014, Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases, Allergo J Int, 23, 282, 10.1007/s40629-014-0032-2 · DOI
  8. James, 2017, Allergen immunotherapy: an updated review of safety, Curr Opin Allergy Clin Immunol, 17, 55, 10.1097/ACI.0000000000000335 · DOI
  9. Hellkvist, 2018, Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: a randomized, double-blind, placebo-controlled trial, J Allergy Clin Immunol, 142, 1338, 10.1016/j.jaci.2018.05.030 · DOI
  10. Hellkvist, 2022, High-dose pollen intralymphatic immunotherapy: two RDBPC trials question the benefit of dose increase, Allergy, 77, 883, 10.1111/all.15042 · DOI
  11. Konradsen, 2020, Intralymphatic immunotherapy in pollen-allergic young adults with rhinoconjunctivitis and mild asthma: a randomized trial, J Allergy Clin Immunol, 145, 1005, 10.1016/j.jaci.2019.11.017 · DOI
  12. Skaarup, 2021, The number of successful injections associates with improved clinical effect in intralymphatic immunotherapy, Allergy, 76, 1859, 10.1111/all.14642 · DOI
  13. Skaarup, 2021, Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: a 3-year randomized placebo-controlled trial, J Allergy Clin Immunol, 147, 1011, 10.1016/j.jaci.2020.07.002 · DOI
  14. Hylander, 2013, Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis, J Allergy Clin Immunol, 131, 412, 10.1016/j.jaci.2012.10.056 · DOI · Paper page
  15. Aini, 2021, Efficacy and safety of intralymphatic immunotherapy in allergic rhinitis: a systematic review and meta-analysis, Clin Transl Allergy, 11, 10.1002/clt2.12055 · DOI
  16. Hoang, 2021, Intralymphatic immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis, Rhinology, 59, 236
  17. Werner, 2021, Intralymphatic immunotherapy for allergic rhinitis: a systematic review and meta-analysis, Allergy Asthma Proc, 42, 283, 10.2500/aap.2021.42.210028 · DOI
  18. Moher, 2012, CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials, Int J Surg, 10, 28, 10.1016/j.ijsu.2011.10.001 · DOI · Paper page
  19. Juniper, 1991, Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis, Clin Exp Allergy, 21, 77, 10.1111/j.1365-2222.1991.tb00807.x · DOI
  20. Juniper, 1999, Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire, J Allergy Clin Immunol, 104, 364, 10.1016/S0091-6749(99)70380-5 · DOI
  21. Durham, 1999, Long-term clinical efficacy of grass-pollen immunotherapy, N Engl J Med, 341, 468, 10.1056/NEJM199908123410702 · DOI
  22. Fritzsching, 2022, Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: results from the REACT study, a retrospective cohort study, Lancet Reg Health Eur, 13
  23. Bender, 2016, Solving the problem of nonadherence to immunotherapy, Immunol Allergy Clin North Am, 36, 205, 10.1016/j.iac.2015.08.014 · DOI
  24. Senti, 2009, Intralymphatic immunotherapy, Curr Opin Allergy Clin Immunol, 9, 537, 10.1097/ACI.0b013e3283310ff7 · DOI
  25. Bachmann, 2017, Allergen-specific immunotherapy: is it vaccination against toxins after all?, Allergy, 72, 13, 10.1111/all.12890 · DOI
  26. Johansen, 2005, Direct intralymphatic injection of peptide vaccines enhances immunogenicity, Eur J Immunol, 35, 568, 10.1002/eji.200425599 · DOI
  27. Johansen, 2008, Medication with antihistamines impairs allergen-specific immunotherapy in mice, Clin Exp Allergy, 38, 512, 10.1111/j.1365-2222.2007.02904.x · DOI
  28. Johansen, 2005, Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens, Eur J Immunol, 35, 3591, 10.1002/eji.200535076 · DOI
  29. Johansen, 2005, Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy, Clin Exp Allergy, 35, 1591, 10.1111/j.1365-2222.2005.02384.x · DOI
  30. Heinzerling, 2006, Critical role for DNA vaccination frequency in induction of antigen-specific cytotoxic responses, Vaccine, 24, 1389, 10.1016/j.vaccine.2005.09.018 · DOI
  31. Maloy, 2001, Intralymphatic immunization enhances DNA vaccination, Proc Natl Acad Sci U S A, 98, 3299, 10.1073/pnas.051630798 · DOI
  32. Freiberger, 2016, IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT-Feld1 in human, Allergy, 71, 1366, 10.1111/all.12946 · DOI
  33. Senti, 2009, Intralymphatic allergen specific immunotherapy using modified recombinant allergen targeting the MHC class II pathway: a double-blind placebo-controlled clinical trial in cat dander allergic patients, Allergy, 64, 74
  34. Park, 2021, Intralymphatic immunotherapy with tyrosine-adsorbed allergens: a double-blind, placebo-controlled trial, Respir Res, 22, 170, 10.1186/s12931-021-01766-0 · DOI
  35. Lee, 2018, Intralymphatic immunotherapy alleviates allergic symptoms during allergen exposure in daily life, Allergy Asthma Immunol Res, 10, 180, 10.4168/aair.2018.10.2.180 · DOI
  36. Lee, 2017, A pilot study of intralymphatic immunotherapy for house dust mite, cat, and dog allergies, Allergy Asthma Immunol Res, 9, 272, 10.4168/aair.2017.9.3.272 · DOI
  37. Chabot, 2022, Intralymphatic immunotherapy (ILIT) with bee venom allergens: a clinical proof of concept study and the very first ILIT in human, Front Allergy, 3, 10.3389/falgy.2022.832010 · DOI
  38. Di Lorenzo, 2013, Clinical course of rhinitis and changes in vivo and in vitro of allergic parameters in elderly patients: a long-term follow-up study, Clin Exp Med, 13, 67, 10.1007/s10238-012-0175-8 · DOI
  39. Danielsson, 1997, The natural course of allergic rhinitis during 12 years of follow-up, Allergy, 52, 331, 10.1111/j.1398-9995.1997.tb00999.x · DOI
  40. Tizek, 2022, Urban vs rural – prevalence of self-reported allergies in various occupational and regional settings, World Allergy Org J, 15, 10.1016/j.waojou.2022.100625 · DOI

Cited by

Sorted by citations

Metadata

Authors
Adlany, Y. K., Šošić, L., Senti, G., Lang, C. C. V., Wüthrich, B., Kündig, T. M., & Johansen, P.
Affiliations
  • University of Zurich (CH)
  • University Hospital Zurich (CH)
Corresponding author
Johansen, Pål
ORCID
Venue
Journal of Allergy and Clinical Immunology: Global
Publisher
Elsevier BV
Published
2023-02
Volume
2
Issue
1
Pages
43-50
ISSN
2772-8293 (ISSN-L)
DOI
10.1016/j.jacig.2022.09.007
PMC
PMC10509981
OpenAlex
W4307723828
Cited by
9
References
3
Citations by year
2026: 2 · 2025: 3 · 2024: 2 · 2023: 2
FWCI
1.26
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Allergy and Clinical Immunology Global (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Universitätsspital Zürich
  • Allergy Therapeutics
Topics
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
  • Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
Keywords
intralymphatic immunotherapy, allergic rhinitis, grass pollen allergy, subcutaneous immunotherapy, quality of life, long-term treatment efficacy, Rhinoconjunctivitis Quality of Life Questionnaire, patient satisfaction, allergen immunotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review